PL2575873T3 - Zatężanie i liofilizacja antygenów szczepionkowych grypy - Google Patents
Zatężanie i liofilizacja antygenów szczepionkowych grypyInfo
- Publication number
- PL2575873T3 PL2575873T3 PL11745827T PL11745827T PL2575873T3 PL 2575873 T3 PL2575873 T3 PL 2575873T3 PL 11745827 T PL11745827 T PL 11745827T PL 11745827 T PL11745827 T PL 11745827T PL 2575873 T3 PL2575873 T3 PL 2575873T3
- Authority
- PL
- Poland
- Prior art keywords
- lyophilization
- concentration
- influenza vaccine
- vaccine antigens
- antigens
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 238000004108 freeze drying Methods 0.000 title 1
- 229960003971 influenza vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16251—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39672010P | 2010-06-01 | 2010-06-01 | |
| EP11745827.3A EP2575873B1 (en) | 2010-06-01 | 2011-06-01 | Concentration and lyophilization of influenza vaccine antigens |
| PCT/IB2011/001564 WO2011151726A2 (en) | 2010-06-01 | 2011-06-01 | Concentration of vaccine antigens with lyophilization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2575873T3 true PL2575873T3 (pl) | 2016-06-30 |
Family
ID=44503998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11745827T PL2575873T3 (pl) | 2010-06-01 | 2011-06-01 | Zatężanie i liofilizacja antygenów szczepionkowych grypy |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130243841A1 (pl) |
| EP (1) | EP2575873B1 (pl) |
| JP (1) | JP5976639B2 (pl) |
| KR (1) | KR20130081659A (pl) |
| CN (1) | CN102939104A (pl) |
| AU (1) | AU2011262312B2 (pl) |
| BR (1) | BR112012030616A2 (pl) |
| CA (1) | CA2801151A1 (pl) |
| EA (1) | EA201291404A1 (pl) |
| ES (1) | ES2564096T3 (pl) |
| NZ (1) | NZ603863A (pl) |
| PL (1) | PL2575873T3 (pl) |
| PT (1) | PT2575873E (pl) |
| WO (1) | WO2011151726A2 (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2531577T3 (es) | 2010-08-20 | 2015-03-17 | Novartis Ag | Conjuntos de agujas para la administración de vacuna soluble contra la gripe |
| WO2012158483A2 (en) | 2011-05-16 | 2012-11-22 | Avery Dennison Corporation | Adhesive containing microparticles |
| US20140322299A1 (en) * | 2011-11-17 | 2014-10-30 | Avery Dennison Corporation | Controlled Release of Active Using pH |
| CN103242434B (zh) * | 2012-02-08 | 2020-03-17 | 长春百克生物科技股份公司 | 无细胞百日咳疫苗的制备方法 |
| KR102242908B1 (ko) | 2013-02-07 | 2021-04-20 | 애버리 데니슨 코포레이션 | 개선된 특성을 지니는 항미생물 접착제 |
| US10137186B2 (en) * | 2013-03-14 | 2018-11-27 | Takeda Vaccines, Inc. | Compositions and methods for live, attenuated alphavirus formulations |
| US11213432B2 (en) | 2013-03-15 | 2022-01-04 | Avery Dennison Corporation | Transparent cover dressing application system and inclusion of label strip |
| RU2720808C2 (ru) | 2013-09-03 | 2020-05-13 | Джорджия Тек Рисёч Корпорейшн | Термостабильные препараты вакцин и микроиглы |
| US10258687B2 (en) * | 2014-04-16 | 2019-04-16 | Hvidovre Hospital | Development of methods for production of a whole virus vaccine candidate stock and novel adaptive mutations in hepatitis C virus |
| WO2015188031A2 (en) | 2014-06-05 | 2015-12-10 | Avery Dennison Corporation | Articles with active agent concentrated at the substrate contacting surface and related methods |
| US10280404B2 (en) | 2014-10-28 | 2019-05-07 | Hvidovre Hospital | Optimized HCV full-length infectious cell culture systems and applications thereof |
| JP7432506B2 (ja) | 2017-10-30 | 2024-02-16 | 武田薬品工業株式会社 | 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤 |
| EP3749755B1 (en) | 2018-02-09 | 2024-06-12 | Hvidovre Hospital | Efficient cell culture system for hepatitis c virus genotype 6a |
| MX2022002980A (es) | 2019-09-16 | 2022-04-06 | Amgen Inc | Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos. |
| EP4212873B1 (en) | 2020-09-11 | 2026-04-08 | FUJIFILM Corporation | Concentration device, method for concentrating sample solution, method for testing sample solution, and test kit |
| CN114931557B (zh) * | 2022-03-18 | 2023-07-07 | 辽宁成大生物股份有限公司 | 一种冻干保护剂、疫苗冻干制剂及其制备方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
| EP0872478B1 (en) | 1991-03-01 | 2002-12-18 | Minnesota Mining And Manufacturing Company | Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
| PT733113E (pt) | 1994-01-11 | 2007-08-10 | Vlaams Interuniv Inst Biotech | Vacina contra a gripe |
| CA2184132C (en) * | 1995-09-21 | 2011-03-15 | Kristina J. Hennessy | An adjuvanted vaccine which is substantially free of non-host albumin |
| DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| AU7126998A (en) | 1997-04-16 | 1998-11-11 | Connaught Laboratories Inc. | Anti-influenza compositions supplemented with neuraminidase |
| US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
| US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
| KR20020038771A (ko) | 1999-09-24 | 2002-05-23 | 장 스테판느 | 비내 인플루엔자 바이러스 백신 |
| EP1260581B1 (en) | 2000-03-03 | 2010-07-07 | Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute | Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell |
| FR2808803B1 (fr) | 2000-05-11 | 2004-12-10 | Agronomique Inst Nat Rech | Cellules es modifiees et gene specifique de cellules es |
| GB0017999D0 (en) * | 2000-07-21 | 2000-09-13 | Smithkline Beecham Biolog | Novel device |
| ES2327103T3 (es) * | 2000-09-25 | 2009-10-26 | Polymun Scientific Immunbiologische Forschung Gmbh | Vacuna viva de influenzavirus y procedimiento de fabricacion. |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| US7803392B2 (en) | 2000-12-27 | 2010-09-28 | University Of Kentucky Research Foundation | pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules |
| DE60239594D1 (de) | 2001-02-23 | 2011-05-12 | Glaxosmithkline Biolog Sa | Influenza vakzinzusammensetzungen zur intradermaler verabreichung |
| US20040096463A1 (en) | 2001-02-23 | 2004-05-20 | Nathalie Garcon | Novel vaccine |
| WO2002087494A2 (en) * | 2001-04-27 | 2002-11-07 | Glaxosmithkline Biologicals, Sa | Novel vaccine |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| EP1399131A2 (en) * | 2001-06-08 | 2004-03-24 | Powderject Vaccines, Inc. | Spray freeze-dried compositions |
| DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
| DE10144903A1 (de) | 2001-09-12 | 2003-03-27 | Chiron Behring Gmbh & Co | Vermehrung von Viren in Zellkultur |
| FR2832423B1 (fr) | 2001-11-22 | 2004-10-08 | Vivalis | Systeme d'expression de proteines exogenes dans un systeme aviaire |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
| WO2004084816A2 (en) * | 2003-03-21 | 2004-10-07 | Progenics Pharmaceuticals, Inc. | IMPROVED CD4-IgG2 FORMULATIONS |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| CA2562932A1 (en) * | 2004-04-01 | 2005-10-27 | Alza Corporation | Apparatus and method for transdermal delivery of influenza vaccine |
| WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
| JP2008507590A (ja) * | 2004-05-19 | 2008-03-13 | アルザ コーポレイション | 免疫活性剤を経皮送達するための方法及び配合物 |
| NZ551640A (en) | 2004-05-20 | 2010-05-28 | Id Biomedical Corp | Process for the production of an influenza vaccine |
| PT1789084E (pt) | 2004-09-09 | 2011-02-22 | Novartis Vaccines & Diagnostic | Redução de riscos iatrogénicos pontenciais associados às vacinas contra a gripe |
| DK2368975T3 (en) | 2004-12-23 | 2015-01-05 | Medimmune Llc | Non-tumorigenic MDCK cell line for the propagation of viruses |
| FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| JP5161776B2 (ja) | 2005-09-06 | 2013-03-13 | セラジェクト， インコーポレイテッド | 薬物粒子および／または薬物を吸着した粒子を含む、固溶体穿孔器 |
| WO2007052163A2 (en) | 2005-11-01 | 2007-05-10 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment |
| WO2007061781A1 (en) | 2005-11-18 | 2007-05-31 | 3M Innovative Properties Company | Coatable compositions, coatings derived therefrom and microarrays having such coatings |
| CA2627542A1 (en) | 2005-11-18 | 2007-05-24 | 3M Innovative Properties Company | Microneedle arrays and methods of preparing same |
| US20090171314A1 (en) | 2006-04-20 | 2009-07-02 | Ferguson Dennis E | Molded articles comprising microneedle arrays |
| PL2121011T3 (pl) | 2006-12-06 | 2014-10-31 | Novartis Ag | Szczepionki zawierające antygeny czterech szczepów wirusa grypy |
| CN101784283A (zh) | 2007-06-27 | 2010-07-21 | 诺华有限公司 | 低添加流感疫苗 |
| WO2010002418A2 (en) | 2008-07-01 | 2010-01-07 | The Johns Hopkins University | Quick-dissolving oral thin film for targeted delivery of therapeutic agents |
| BRPI0918253A2 (pt) * | 2008-09-12 | 2015-12-15 | Critical Pharmaceuticals Ltd | aperfeicoamento na absorcao de agentes terapeuticos atraves das membranas mucosas ou da pele |
-
2011
- 2011-06-01 CN CN201180027227XA patent/CN102939104A/zh active Pending
- 2011-06-01 CA CA2801151A patent/CA2801151A1/en not_active Abandoned
- 2011-06-01 ES ES11745827.3T patent/ES2564096T3/es active Active
- 2011-06-01 PL PL11745827T patent/PL2575873T3/pl unknown
- 2011-06-01 BR BR112012030616A patent/BR112012030616A2/pt not_active IP Right Cessation
- 2011-06-01 EA EA201291404A patent/EA201291404A1/ru unknown
- 2011-06-01 AU AU2011262312A patent/AU2011262312B2/en not_active Ceased
- 2011-06-01 NZ NZ603863A patent/NZ603863A/en not_active IP Right Cessation
- 2011-06-01 WO PCT/IB2011/001564 patent/WO2011151726A2/en not_active Ceased
- 2011-06-01 EP EP11745827.3A patent/EP2575873B1/en not_active Not-in-force
- 2011-06-01 PT PT117458273T patent/PT2575873E/pt unknown
- 2011-06-01 KR KR1020127032670A patent/KR20130081659A/ko not_active Ceased
- 2011-06-01 JP JP2013513005A patent/JP5976639B2/ja not_active Expired - Fee Related
- 2011-06-01 US US13/700,437 patent/US20130243841A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2564096T3 (es) | 2016-03-17 |
| AU2011262312A1 (en) | 2012-12-20 |
| BR112012030616A2 (pt) | 2017-03-01 |
| WO2011151726A2 (en) | 2011-12-08 |
| EP2575873B1 (en) | 2015-12-30 |
| NZ603863A (en) | 2014-09-26 |
| JP2013527225A (ja) | 2013-06-27 |
| EP2575873A2 (en) | 2013-04-10 |
| EA201291404A1 (ru) | 2013-05-30 |
| PT2575873E (pt) | 2016-03-04 |
| KR20130081659A (ko) | 2013-07-17 |
| WO2011151726A3 (en) | 2012-02-02 |
| CA2801151A1 (en) | 2011-12-08 |
| CN102939104A (zh) | 2013-02-20 |
| JP5976639B2 (ja) | 2016-08-23 |
| US20130243841A1 (en) | 2013-09-19 |
| AU2011262312B2 (en) | 2015-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2575873E (pt) | Concentração de antigénios de vacinas com liofilização | |
| IL262123A (en) | Influenza virus vaccines and uses thereof | |
| IL261204A (en) | Influenza virus vaccines and their use | |
| PT2575872T (pt) | Concentração de antigénios da vacina da gripe sem liofilização | |
| EP2552479A4 (en) | INFLUENZA VIRUS VACCINES AND USES THEREOF | |
| IL248607A (en) | Methods and compositions for immunization against virus | |
| ZA201404797B (en) | Influenza virus vaccines and uses thereof | |
| ZA201502991B (en) | Disubstituted amino acids and methods of preparation and use thereof | |
| EP2680885B8 (en) | Combination vaccines with lower doses of antigen and/or adjuvant | |
| IL223424B (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| LT2710033T (lt) | Žmogaus imunodeficito virusą neutralizuojantys antikūnai ir jų panaudojimo būdai | |
| BR112014010658A2 (pt) | antígenos e vacinas direcionadas contra enterovírus humano | |
| SG10201503450WA (en) | Vaccine against beta-herpesvirus infection and use thereof | |
| ZA201205824B (en) | Vaccine vectors and methods of enhancing immune responses | |
| SG11201404147YA (en) | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza | |
| HUE046858T2 (hu) | Vakcina és eljárások campylobacter fertõzés csökkentésére | |
| EP2595653A4 (en) | INFLUENZA VACCINE | |
| IL225389A0 (en) | Antibody compositions and methods of use | |
| EP3494989C0 (en) | COMPOSITE ANTIGEN SEQUENCES AND VACCINES | |
| EP2525782A4 (en) | FORMULATIONS FROM NANOTRÄGERN AND METHOD FOR THE PRODUCTION THEREOF | |
| EP2408913A4 (en) | NEIL3-PEPTIDES AND VACCINES CONTAINING THEM | |
| EP2588135A4 (en) | Nanoemulsion vaccines | |
| EP2771350A4 (en) | TOPK PEPTIDES AND VACCINES CONTAINING THEM | |
| EP2632941A4 (en) | RECOMBINANT HEMAGGLUTININE PROTEIN OF THE INFLUENZA VIRUS AND VACCINE THEREWITH | |
| EP2895600A4 (en) | UBE2T-4-PEPTIDES AND VACCINES THEREWITH |